Rethinking Remdesivir: Synthesis, Antiviral Activity, and Pharmacokinetics of Oral Lipid Prodrugs

@article{Schooley2021RethinkingRS,
  title={Rethinking Remdesivir: Synthesis, Antiviral Activity, and Pharmacokinetics of Oral Lipid Prodrugs},
  author={Robert T. Schooley and Aaron F. Carlin and James R. Beadle and Nadejda Valiaeva and Xing-quan Zhang and Alex E. Clark and Rachel E. McMillan and Sandra Lawrynowicz Leibel and Rachael N. McVicar and Jia-zheng Xie and Aaron F. Garretson and Victoria I. Smith and Joyce Murphy and Karl Y. Hostetler},
  journal={Antimicrobial Agents and Chemotherapy},
  year={2021},
  volume={65}
}
Remdesivir (RDV; GS-5734) is currently the only FDA-approved antiviral drug for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The drug is approved for use in adults or children 12 years or older who are hospitalized for the treatment of COVID-19 on the basis of an acceleration of clinical recovery for inpatients with this disease. ABSTRACT Remdesivir (RDV; GS-5734) is currently the only FDA-approved antiviral drug for the treatment of severe acute… 
5 Citations
Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19
TLDR
The authors believe that molnupiravir meets these requirements and is a breakthrough COVID-19 treatment, and anticipate patent filing related to oral dosage forms, inhalers, and a combination of moln UPIRavir with marketed drugs like remdesivir, favipiravIR, and baricitinib.
Remdesivir and Its Combination With Repurposed Drugs as COVID-19 Therapeutics
TLDR
Remdesivir targets the SARS-CoV-2 enzyme while baricitinib targets the host human enzyme and simultaneously inhibit their target viral RdRp and human Janus kinase, respectively.
Nucleoside analog GS‐441524: pharmacokinetics in different species, safety, and potential effectiveness against Covid‐19
TLDR
D doses of GS‐441524 lower than the 13 mg/kg dose used in the first‐in‐human trial may be effective against Covid‐19 and appears to be well‐tolerated, and GS‐ 441524 has potential for oral treatment of Covid-19.

References

SHOWING 1-10 OF 61 REFERENCES
Rethinking Remdesivir: Synthesis, Antiviral Activity and Pharmacokinetics of Oral Lipid Prodrugs
TLDR
New oral lipid prodrugs of Remdesivir nucleoside had submicromolar anti-SARS-CoV-2 activity in a variety of cell types including Vero E6, Calu-3, Caco-2, human pluripotent stem cell (PSC)-derived lung cells and Huh7.5 cells.
Remdesivir for the Treatment of Covid-19 — Final Report
TLDR
The data show that remdesivir was superior to placebo in shortening the time to recovery in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection.
Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2
TLDR
The data support the early initiation of remdesivir treatment in patients with COVID-19 to prevent progression to pneumonia and reduce viral load and lung disease in a rhesus macaque model of SARS-CoV-2 infection.
Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection
TLDR
The data show that remdesivir is a promising antiviral treatment against MERS that could be considered for implementation in clinical trials, and may also have utility for related coronaviruses such as the novel coronavirus 2019-nCoV emerging from Wuhan, China.
Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2
TLDR
Therapeutic remdesivir treatment initiated early during infection has a clear clinical benefit in SARS-CoV-2-infected rhesus macaques and these data support early remdesavir treatment initiation in COVID-19 patients to prevent progression to severe pneumonia.
Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19
TLDR
The first pharmacokinetic evaluation of remdesivir and GS-441524 in recovered COVID-19 patients is reported, and levels in lung and CNS suggest compartmental differences in drug exposure.
Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19
TLDR
An overview of remdesivir’s discovery, mechanism of action, and the current studies exploring its clinical effectiveness is provided.
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
TLDR
A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older and safety over a median of 2 months was similar to that of other viral vaccines.
Oral Treatment of Murine Cytomegalovirus Infections with Ether Lipid Esters of Cidofovir
TLDR
Oral treatment with HDP-CDV or ODE- CDV given orally was as effective as parenteral CDV for the treatment of experimental MCMV infection and suggest that further evaluation for use in CMV infections in humans is warranted.
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
TLDR
The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease, and Aside from transient local and systemic reactions, no safety concerns were identified.
...
...